12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

MGN-4893 regulatory update

FDA granted Orphan Drug designation for miRagen's MGN-4893 to treat polycythemia vera....

Read the full 38 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >